NICE Supports Takeda’s Revestive for People With Short Bowel Syndrome

The UK’s National Institute for Health and Care Excellence (NICE) recommended Takeda’s Revestive (teduglutide) for National Health Service (NHS) use in people with short bowel syndrome who are in a stable condition following bowel removal surgery.

The agency said that Revestive helps improve the absorption of nutrients and fluid from the remaining intestine. Clinical trial results demonstrated that the drug reduced the number of days per week patients needed parenteral support compared with those treated with a placebo.

With the currently available treatments, patients with short bowel syndrome need parenteral support as much as 14 hours a day, seven days a week, NICE noted.

Revestive’s listed price is more than $650 per 5 mg vial. The discounted price for NHS use was not disclosed.